Silence Therapeutics PLC Save the Date: Capital Markets Event 14 November (7143O)

TIDMSLN

RNS Number : 7143O

Silence Therapeutics PLC

23 August 2017

Silence to host Capital Markets event on 14 November 2017

23 August 2017

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that the Company will host a Capital Markets event for investors, analysts and media at ME London Hotel, Strand, London WC2R 1HA on Tuesday 14 November between 3:00pm and 5:30pm GMT.

At the meeting, Silence will provide an update on its RNAi pipeline and proprietary technology platforms, as well as a review of the Company's strategy. Further details will follow in due course.

To register your interest, please contact [e-mail].

Enquiries:

 
 Silence Therapeutics plc                Tel: +44 (0)20 
  Ali Mortazavi, Chief Executive          3457 6900 
  Officer 
  David Ellam, Chief Financial Officer 
 
 Peel Hunt LLP (Nominated Adviser        Tel: +44 (0)20 
  and Broker)                             7418 8900 
  James Steel/Oliver Jackson 
 Media Enquiries:                        Tel: +44 (0) 20 
  FTI Consulting                          3727 1000 
  Simon Conway/Brett Pollard/Stephanie 
  Cuthbert 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCPGUGCRUPMGMP

(END) Dow Jones Newswires

August 23, 2017 02:00 ET (06:00 GMT)